Long-term Balancing Act: Incentives and FOBs Pathway
This article was originally published in RPM Report
Executive Summary
As Congress finishes its work on a pathway for follow-on biologics, a number of key decisions affecting incentives for copies and innovative products remain. No matter how the new legislation turns out, a number of issues will remain to be worked out in practice and will dominate investment and drug development policy for decades to come.